| Code | CSB-RA013481MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Zagotenemab, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing microtubules in neurons, essential for maintaining axonal transport and neuronal structure. Under pathological conditions, MAPT becomes hyperphosphorylated and aggregates into neurofibrillary tangles, a hallmark of tauopathies including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. These tau aggregates disrupt neuronal function and correlate with cognitive decline and neurodegeneration.
Zagotenemab is a humanized IgG4 monoclonal antibody that binds to the misfolded and aggregated tau proteins with great affinity, but has very weak binding force for the normal monomeric tau proteins. It identifies and removes the abnormal aggregations of tau proteins in the brain, aiming to block or delay the spread of pathological tau proteins between brain cells, thereby inhibiting the formation of neurofibrillary tangles and the damage to neurons. This biosimilar provides researchers with a valuable tool for investigating tau biology, studying mechanisms of tau-mediated neurodegeneration, and exploring potential therapeutic interventions in tauopathies. It supports research into tau pathology, protein aggregation dynamics, and neurodegenerative disease mechanisms.
There are currently no reviews for this product.